Nexalin Technology, Inc. (NXL – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Anthony Vendetti from Maxim Group maintained a Buy rating on the stock and has a $5.00 price target.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Anthony Vendetti has given his Buy rating due to a combination of factors that highlight Nexalin Technology, Inc.’s promising advancements and strategic positioning in the mental health treatment sector. The company has made significant progress in regulatory and commercial pathways, particularly with its Gen-2 Sync system aimed at treating Alzheimer’s disease and dementia. This progress is supported by favorable internal data, preliminary FDA feedback, and recent peer-reviewed publications, which bolster confidence in the company’s innovative technology.
Additionally, Nexalin’s financial position appears stable, with sufficient capital to support operations into the second quarter of 2026, following a recent capital raise. The company’s strategic initiatives, such as the reconstitution of its Scientific Advisory Board and the launch of its virtual clinic platform, further enhance its capability to conduct remote treatments and capture real-time data. These developments, along with the potential international market expansion indicated by recent IRB approval in Brazil, reinforce the long-term value potential of Nexalin’s non-invasive neurostimulation technology, justifying the Buy rating.
According to TipRanks, Vendetti is an analyst with an average return of -25.3% and a 24.29% success rate. Vendetti covers the Healthcare sector, focusing on stocks such as Dermata Therapeutics, Strata Skin Sciences, and Rockwell Med.